share_log

Monitoring Cardiac Symptoms? HeartBeam Extends Pact With Samsung For LIVMOR Solutions

Monitoring Cardiac Symptoms? HeartBeam Extends Pact With Samsung For LIVMOR Solutions

監測心臟症狀？HeartBeam 延長了與三星在 LIVMOR 解決方案
Benzinga ·  2023/05/30 12:03
  • HeartBeam, Inc. (NASDAQ:BEAT) shares are trading higher after entering a strategic alliance agreement with Samsung Electronics Co Ltd (OTC:SSNGY) (OTC:SSNLF).
  • The deal extends the existing pact between HeartBeam's recently-acquired LIVMOR and Samsung. The financial terms were not disclosed.
  • Under the latest deal, HeartBeam and Samsung will assess and monitor cardiac symptoms, tapping the HeartBeam's patented technology.
  • "Our newly acquired state of the art, FDA cleared, Samsung watch-based arrhythmia detection tool, once integrated with the HeartBeam AIMIGo telehealth platform, presents a unique opportunity to extend our product capabilities well beyond what is currently available for cardiac patients outside of a medical setting," said Branislav Vajdic, Ph.D., HeartBeam CEO and Founder.
  • HeartBeam acquired the assets of LIVMOR earlier this year. Founded in 2016, LIVMOR developed the Halo Atrial Fibrillation (AF) Detection System, the world's first FDA-cleared prescription wearable for continuous cardiac rhythm monitoring.
  • The potential of combining LIVMOR's technology and the HeartBeam AIMIGo system holds significant promise to address primary cardiac conditions for veterans.
  • Price Action: BEAT shares are trading higher by 7.6% to $2.34 on the last check Tuesday.
  • HeartBeam, Inc 納斯達克股票代碼：BEAT）在與達成戰略聯盟協議後，股價走高 三星電子有限公司 (OTC: SSNGY) (OTC: SSNLF)。
  • 該交易延長了HeartBeam最近收購的LIVMOR與三星之間的現有協議。財務條款未披露。
  • 根據最新協議，HeartBeam和三星將利用HeartBeam的專利技術評估和監測心臟症狀。
  • HeartBeam首席執行官兼創始人布拉尼斯拉夫·瓦伊迪奇博士說：“我們新收購的最先進的、經美國食品藥品管理局批准的基於三星手錶的心律失常檢測工具一旦與HeartBeam AimiGo遠程醫療平臺集成，爲我們的產品能力提供了一個難得的機會。”
  • HeartBeam在今年早些時候收購了LIVMOR的資產。LIVMOR 成立於 2016 年，開發了 Halo 心房顫動 (AF) 檢測系統，這是世界上第一款經美國食品藥品管理局批准的用於持續心律監測的處方可穿戴設備。
  • 將LIVMOR的技術與HeartBeam AimiGo系統相結合的潛力爲退伍軍人解決原發性心臟病帶來了巨大希望。
  • 價格走勢： 在週二的最後一張支票中，BEAT股價上漲了7.6％，至2.34美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論